Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Cheung

Plastic and Reconstructive Surgery Fort Lauderdale, FL Medical Doctor

NPI 1972736650 CMS profile 1366638

906 Ne 26Th Ave, Fort Lauderdale, FL 33304

Open in the dashboard

General payments

$17,352

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Cheung of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $17,352 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,570 16
2024 General $1,597 15
2023 General $1,224 18
2022 General $831 18
2021 General $764 22
2020 General $1,040 15
2019 General $10,328 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Cheung
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Michael Cheung were reported at $1,570. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Michael Cheung Plastic and Reconstructive Surgery median Middle half National median
2019 $10,328 $335 $121–$1,264 $163
2020 $1,040 $162 $57–$417 $114
2021 $764 $245 $89–$735 $132
2022 $831 $325 $120–$932 $149
2023 $1,224 $343 $129–$999 $160
2024 $1,597 $390 $141–$1,085 $164
2025 $1,570 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $9,636 37 payments
  2. AbbVie, Inc. $1,525 19 payments
  3. Integra LifeSciences Corporation $1,398 27 payments
  4. Musculoskeletal Transplant Foundation Inc. $927 8 payments
  5. AxoGen $538 7 payments
  6. Mentor Worldwide LLC $526 14 payments
  7. Kerecis Limited $398 4 payments
  8. W. L. Gore & Associates, Inc. $330 2 payments
  9. Stryker Corporation $258 3 payments
  10. Innovation Technologies Inc $196 2 payments
  11. Other $1,620 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,136 150 payments
  2. Gift $8,216 4 payments
Products named General payments · program years 2019–2025
  1. NATRELLE $8,881 19 payments
  2. ALLODERM $1,076 14 payments
  3. PRIMATRIX $701 9 payments
  4. INTEGRA DERMAL REGENERATION TEMPLATE $701 9 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS $691 14 payments
  6. AMNIOEXCEL $667 17 payments
  7. FLOWABLE $667 17 payments
  8. INTEGRA WOUND MATRIX (IWM) $667 17 payments
  9. IDRT $667 17 payments
  10. BILAYER WOUND MATRIX (BWM) $667 17 payments
  11. Other $9,558 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

134

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$553

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

35.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 47 $274
Cephalexin Generic 34 $136
Ondansetron Hcl Generic 30 $115
Tramadol Hcl Generic 23 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$33,870

Medicare's payments for the services billed

Medicare patients

54

Average age 73

Services billed

108

25 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Cancer 44%
Ischemic heart disease 43%
Arthritis 39%
Chronic kidney disease 26%
Depression 24%
Osteoporosis 24%
Diabetes 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record